[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Boston University Charles River Campus\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":646},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,41,69,96,121,149,181,213,241,269,295,319,343,367,387,416,437,455,482,510,534,563,586,604,627],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100530089","identifying-and-addressing-barriers-to-retention-in-the-cervical-cancer-treatment-cascade-among-women-with-hiv-in-south-africa-part-2-100530089",false,"NCT06182241","Identifying and Addressing Barriers to Retention in the Cervical Cancer Treatment Cascade Among Women With HIV in South Africa: Part 2","Inclusion Criteria:\n\n* Having a cervix\n* Aged 18+\n* Living with HIV\n* Recent high-risk abnormal Pap results within the last month (if needed, we may increase the range by up to 6 months to ensure that we meet our targets).\n\nExclusion Criteria:\n\n* Younger than 18 years old\n* HIV-negative\n* No cervix\u002Fhistory of hysterectomy\n* Recent normal or low-risk abnormal Pap results\n* Unable to provide informed consent or assent in English or isiZulu and\u002For have a significant psychiatric illness (e.g., active psychotic disorder or untreated bipolar disorder) that could interfere with participation will be excluded. Potential participants will also be asked if they have any health conditions that make it difficult for them to travel to the clinic.","FEMALE","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","The investigators will conduct the formative work that is necessary to develop a novel, multi-level intervention (inclusive of patient- and provider-level components), which will increase awareness of and modify the complex, intersecting factors that contribute to cervical cancer development among cisgender women with HIV (WWH). In Aim 1a, the investigators will explore the multi-level barriers and facilitators to follow-up appointment attendance among WWH who have had a recent high-risk abnormal Pap smear in the past six months, via qualitative interviews with WWH who have either attended at least one follow-up visit (n\\\u003C10) or have not yet attended a follow-up visit (n\\\u003C10). In Aim 1b, the investigators will explore provider awareness of the HIV-cervical cancer relationship and perspectives on barriers to retention in care via qualitative interviews (n\\\u003C8). For Aim 2, The study team will leverage the Aim 1 data, develop a patient-level intervention (1-2 sessions) and a provider toolkit, with the goal of increasing retention in care among WWH who are at heightened risk for cervical cancer. The study team will seek feedback on the manual and the toolkit from providers and from a community advisory board. In Aim 3a, the investigators will test the feasibility and acceptability of the intervention in a pilot randomized control trial (RCT) (n\\\u003C60). The study team will also assess (1) changes in self-efficacy to attend cervical cancer-related healthcare appointments pre-post intervention, (2) the proportion of women who attend a follow-up appointment, and, of those participants, (3) the proportion of women who complete the next phase of treatment. In Aim 3b, the investigators will explore the feasibility of intervention implementation in the clinic and acceptability of the provider-level intervention components in qualitative interviews with providers, clinic staff, the interventionalists, and other key stakeholders (n\\\u003C10).",[26,27],"Cervical Cancer","Hiv","RECRUITING","2026-06-23",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":32},"2025-11-17",{"date":36,"type":20},"2026-06-30",{"name":38,"class":39},"Boston University Charles River Campus","OTHER",3,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":47,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100642131","use-of-a-mobile-brain-body-imaging-approach-to-evaluate-the-effects-of-rhythmic-auditory-stimulation-on-gait-and-brain-function-in-alzheimers-disease-100642131","NCT07659964","Use of a Mobile Brain-Body Imaging Approach to Evaluate the Effects of Rhythmic Auditory Stimulation on Gait and Brain Function in Alzheimer's Disease","Inclusion Criteria:\n\nGeneral Inclusion (both healthy and AD populations):\n\n* Community-dwelling\n* Capable of walking short community distances (approximately 10-15 minutes at a time) without assistance from another person or a device (such as a cane).\n* Able to communicate with researchers\n* Age 50-90 (inclusive)\n\nPopulation-specific Inclusion criteria:\n\n* Healthy -\n\n  * No diagnosis of AD\n* AD population-\n\nCERAD score of \\\u003C1.5 SD from age + education adjusted norms on delayed recall domain or one or more other cognitive domains (i.e. language, attention).\n\nMoCA score between 20-30 MMSE score between 25-30\n\nExclusion Criteria:\n\n* Presence of significant hearing impairment\n* Current orthopedic, neurologic or other medical condition that limits the ability to walk.\n\nThe MOCA, MMSE and CERAD tests will be completed in-person after the participant consents into the study. If the participant is determined to be ineligible based on their performance on these tests (compared to inclusion requirements listed above), they will be informed that they are not eligible for this study and the study visit will be cancelled. They will then be withdrawn from the study; their clinical tests and study documentation will be maintained for the purposes of completeness, but will not be used for any study analyses.",true,"ALL","50 Years","90 Years",{"count":52,"type":20},40,[23],"Alzheimer's Disease (AD) is associated with impairments in both gait and cognition, significantly increasing fall risk. Falls are a leading cause of injury-related disability in older adults, and individuals with AD experience a nearly threefold higher rate of falls compared to neurotypical older adults. There is an urgent need for fall prevention interventions tailored to the unique deficits of individuals with AD. Converging evidence suggests that interventions aiming to reduce fall risk in AD should target both gait and cognition. Rhythmic music interventions, such as Rhythmic Auditory Stimulation (RAS) can harness global brain activation and auditory-motor entrainment to facilitate high-intensity exercise to alleviate AD-related neurocognitive and gait dysfunction. This study aims to assess the neural correlates of gait dysfunction in people with AD, evaluate if baseline neurocognitive impairment is predictive of the effects of RAS, and evaluate RAS benefits for individuals with AD.",[56,57],"Alzheimer Disease (AD)","Mild Cognitive Impairment (MCI)",[59],"RAS","2026-06-17",{"date":62,"type":32},"2026-06-22",{"date":64,"type":32},"2026-06-01",{"date":66,"type":20},"2027-06",{"name":38,"class":39},1,{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":47,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":21,"phases":78,"briefSummary":79,"conditions":80,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100487272","reducing-psychological-barriers-to-prep-persistence-among-pregnant-and-postpartum-women-in-cape-town-south-africa-100487272","NCT05624931","Reducing Psychological Barriers to PrEP Persistence Among Pregnant and Postpartum Women in Cape Town, South Africa","Inclusion Criteria:\n\n* For participants across all three aims are:\n\n  * Female sex\n  * Aged 15+\n  * Pregnant and presenting antenatal care at the Gugulethu MOU\n  * HIV-negative\n  * Recent PrEP initiation (\\\u003C1 month ago) or PrEP adherence challenges, either documented (\\>2 weeks late to pick up PrEP refill) or self-reported\n  * Moderate to severe symptoms of posttraumatic stress and\u002For depression (defined as a score of ≥31 on PTSD Checklist for DSM-5 (PCL-5) and\u002For a score of ≥13 on the Edinburgh Postnatal Depression Scale (EPDS). Cutoff scores may be adjusted by 3-5 points to facilitate recruitment.\n\nExclusion Criteria:\n\n* There are no exclusion criteria with respect to parity or gravidity.\n\n  * Participants who are unable to provide informed consent or assent in English or Xhosa\n  * Have a significant psychiatric illness (e.g., active psychotic disorder or untreated bipolar disorder) that could interfere with participation will be excluded. Positive symptoms of active psychosis or mania will be assessed by the research assistants. They will be trained to identify delusions, hallucinations, disorganized or pressured speech, flight of ideas, and grandiosity as they speak to potential participants.\n  * Potential participants will also be asked if they have any health conditions that make it difficult for them to travel to the clinic.","15 Years",{"count":77,"type":20},118,[23],"Pregnant women in South Africa (SA) are at high risk of HIV acquisition. Pre-exposure prophylaxis (PrEP) use during pregnancy is both safe and effective in preventing HIV. However, posttraumatic stress (associated with intimate partner violence and\u002For other traumas) and depression negatively impact PrEP adherence among women in SA. Addressing posttraumatic stress and depression will likely improve PrEP adherence and persistence (i.e., sustained PrEP adherence over time) during pregnancy and breastfeeding, which are periods of dramatically increased HIV risk. The overarching goal of this proposal is to develop and test the feasibility and acceptability of a cognitive behavioral intervention that targets common underlying factors of posttraumatic stress and depression to improve PrEP adherence and persistence during pregnancy and the postpartum transition. The specific aims of the project are to (1) explore the mechanisms by which posttraumatic stress and depression impact PrEP adherence and persistence during pregnancy via qualitative interviews; (2) develop a brief PrEP adherence and persistence intervention (\\~4 sessions) that reduces the negative impact of psychological mechanisms common to posttraumatic stress and depression on PrEP use, and builds behavioral skills to improve self-care; and (3) evaluate the feasibility, acceptability, and signals of preliminary efficacy of the intervention, which will be integrated into antenatal care, in a pilot randomized controlled trial. All data will be collected in the Midwife Obstetrics Unit (MOU) in Gugulethu, a peri-urban settlement and former township community outside of Cape Town, SA.",[81,82,83,84],"Depression","Posttraumatic Stress Disorder","Pregnancy Related","Medication Adherence",[86],"HIV, pregnancy, PrEP","2026-06-15",{"date":89,"type":32},"2026-06-16",{"date":91,"type":32},"2025-04-17",{"date":93,"type":20},"2027-07-30",{"name":38,"class":39},2,{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":47,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":68},"100605152","project-empower-ocd-100605152","NCT07158801","Project EMPOWER-OCD","A Web-based Single Session Intervention to Reduce Caregiver Distress and Accommodation in Socioeconomically Diverse Caregivers of OCD Patients","Inclusion Criteria:\n\n* be a caregiver for at least one individual with OCD, defined as living in the same household and providing daily care\n* be 18 years old or older\n* the individual they are caring for have clinically significant OCD symptoms, indicated by a score a 16 or above on the self-reported Children's Yale-Brown Obsessive Compulsive Scale - Parent Report (CY-BOCS-PR)\n* speak, read, and write English\n* not be in concurrent family-based CBT treatment for the patient's OCD.\n\nExclusion Criteria:\n\n* does not speak English\n* younger than 18 years old\n* participation in concurrent family-based CBT treatment for the patient's OCD.",{"count":104,"type":20},110,[23],"This research study aims to adapt and evaluate the acceptability and effectiveness of Project EMPOWER-OCD for socioeconomically diverse caregivers of patients with OCD. Designed to reduce obstacles (e.g. months long time commitment, high cost, transportation) to treatment that caregivers may be particularly prone to, project EMPOWER-OCD will provide targeted intervention of accommodation - a well-established, potentially modifiable risk factor for child anxiety, OCD, and its related disorders - in a single, self-guided session via an online format.",[108],"Obsessive-Compulsive Disorder",[110,108,111,112],"Parental Accommodation","Caregiving","Single Session Interventions","2026-06-08",{"date":115,"type":32},"2026-06-10",{"date":117,"type":32},"2025-03-25",{"date":119,"type":20},"2026-09",{"name":38,"class":39},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":47,"sex":48,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":21,"phases":132,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":40},"100572688","future-leaders-program-testing-a-youth-leadership-engagement-and-mindfulness-program-100572688","NCT06736522","Future Leaders Program: Testing a Youth Leadership, Engagement, and Mindfulness Program","Can A Youth Leadership and Mindfulness Program Support Well-being in Adolescence?","FLP","Inclusion Criteria:\n\n* Adolescents ages 14 and older in grades 9-12 during the Fall\u002FWinter or in grades 9-11 during the Spring\n* Enrolled in a partner site in Massachusetts or Illinois\n* Adolescents are only included with parent consent and youth assent if they are under the age of 18. Adolescents at least 18 years old can provide consent.\n\nExclusion Criteria:\n\n* They participated in the pilot phase (UG3)\n* They cannot commit to participation in the full study (e.g., attendance at all intervention sessions)\n* They are not in grades 9-12 at a partner site\n* Parent\u002Fguardian has a preferred consent language other than English or Spanish.","14 Years",{"count":131,"type":20},504,[23],"The current study tests the feasibility and effectiveness of a youth intervention designed to provide meaningful leadership opportunities through the acquisition of leadership skills as well as mindfulness practice, LEAP: Leadership, Engagement, and youth Action Program with Mindfulness.\n\nThe goal of this project is to determine whether the Leadership, Engagement, and youth Action Program with Mindfulness (LEAP) curriculum, which was developed with youth, is a feasible and effective intervention for fostering leadership and well-being. The investigators seek to understand whether LEAP can support wellbeing for youth as a strategy to increase youth mental, emotional, and behavioral (MEB) health.",[135,136],"Adolescent Behavior Problem","Mental Health Wellness 1",[138,139,140],"mindfulness","youth leadership","youth wellbeing","2026-06-02",{"date":143,"type":32},"2026-06-04",{"date":145,"type":32},"2024-12-16",{"date":147,"type":20},"2028-03",{"name":38,"class":39},{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":47,"sex":48,"minAge":156,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":159,"briefSummary":160,"conditions":161,"keywords":166,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":68},"100638794","word-learning-in-bilingual-typical-and-late-talking-children-the-role-of-meaning-and-input-100638794","NCT07600242","Word Learning in Bilingual Typical and Late Talking Children: The Role of Meaning and Input","Dual Language Input, Semantic Structure and Word Learning in Typically Developing and Late Talking Bilingual Children","Inclusion Criteria:\n\n* At least 10% exposure to both English and Spanish or at least 90% exposure to English and another language\n\nExclusion Criteria:\n\n* Hearing impairment\n* Uncorrected visual impairment\n* Neurological impairment\n* Genetic syndromes\n* Neurodevelopmental disabilities (e.g. autism)\n* More than 10% exposure to a language other than English or Spanish","24 Months","30 Months",{"count":19,"type":20},[23],"The goal of this clinical trial is to understand how different types of word categories, along with the language children hear from their parents, support bilingual toddlers' word learning. This study will address two main questions: (1) How are the words toddlers know related to the words their parents use? and (2) How does what toddlers already know help them learn new words in two languages? The investigators will compare bilingual toddlers with typical development to those with language delay to determine whether they learn new words in similar ways.\n\nChildren's vocabulary knowledge will be assessed using standardized parent-report checklists. To examine how different types of categories support learning, the study will focus on two early-acquired categories: animals and clothing. The investigators will compare what parents report about their children's vocabulary with how children learn new words within each category.\n\nTo understand the role of parent input, children and their parents will engage in shared book reading and play activities using materials from one of the target categories. Parent-child interactions will be video recorded. Children will also complete an eye-tracking task in which they learn new words in two languages within the same category.",[162,163,164,165],"Bilingualism","Vocabulary Acquisition","Late Talkers","Network Science",[167,168,169,170,171,172],"bilingualism","late talkers","parent input","toddlers","word learning","vocabulary","2026-05-19",{"date":175,"type":32},"2026-05-20",{"date":177,"type":32},"2025-12-16",{"date":179,"type":20},"2029-07-31",{"name":38,"class":39},{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":47,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":187,"targetDuration":4,"studyType":21,"phases":189,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":68},"100491752","neural-markers-of-treatment-mechanisms-and-prediction-of-treatment-outcomes-in-social-anxiety-100491752","NCT05683223","Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety","Inclusion criteria for all participants:\n\n(1) Any gender or race between 18-50 years old.\n\nAdditional inclusion criteria for healthy controls:\n\n(1) Liebowitz Social Anxiety Scale (LSAS; Mennin et al., 2002) score \\\u003C= 30, does not currently meet criteria for an Axis I psychiatric condition, as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5; American Psychiatric Association, 2013).\n\nAdditional inclusion criteria for the social anxiety disorder (SAD) group:\n\n1. Outpatients with a primary psychiatric complaint (designated by the patient as the most important source of current distress) of social anxiety with social interaction fear as defined by an Liebowitz Social Anxiety Scale (LSAS) score \\>= 60.\n2. Overall clinical severity of at least mild as defined by Clinical Global Impressions Scale (CGI-S; Zaider et al., 2003) of at least 3.\n3. Medical history interview and laboratory findings without clinically significant abnormalities.\n4. Willingness and ability to participate in the informed consent process and comply with the requirements of the study protocol.\n\nExclusion criteria:\n\n1. A lifetime history of bipolar disorder, schizophrenia, psychosis, delusional disorders or obsessive-compulsive disorder; an eating disorder in the past 6 months; organic brain syndrome, intellectual disability, or other cognitive dysfunction that could interfere with capacity to engage in therapy; a history of substance or alcohol abuse or dependence (other than nicotine) in the last 6 months or otherwise unable to commit to refraining from alcohol, marijuana, and stimulant use during the acute period of study participation.\n2. . Patients with significant suicidal ideation Montgomery-Åsberg Depression Rating Scale (10 items, self-report) or who have enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.\n3. Patients can be taking a concurrent psychotropic medication (e.g., antidepressants, anxiolytics, beta blockers, sertraline), but the dose must be stabilized for at least 2 weeks prior to initiation of randomized treatment.\n4. Significant personality dysfunction likely to interfere with study participation.\n5. Serious medical illness, associated treatment, or other instability for which hospitalization may be likely within the next year, or which may alter fMRI or EEG measurements. Participants with a history of serious medical illness or treatments that may alter fMRI measurements may enroll in the study 12 months after the condition has been remitted and ending treatment.\n6. Patients with a current or past history of seizures.\n7. Pregnant women, lactating women, and women of childbearing potential who may become pregnant.\n8. Any concurrent psychotherapy initiated within 3 months of baseline, or ongoing psychotherapy of any duration directed specifically toward treatment of the social anxiety is excluded. Individuals with prior CBT experience or treatments that included cognitive and behavioral skills and exposure procedures (e.g., assertiveness and social skills trainings) will be excluded. General supportive or insight-oriented therapy initiated \\> 3 months prior is acceptable.\n9. Prior non-response to adequately-delivered exposure (i.e., as defined by the patient's report of receiving specific and regular exposure assignments as part of a previous treatment).\n10. Patients with a history of head trauma causing loss of consciousness, seizure or ongoing cognitive impairment.\n11. Contraindications for MRI including metal implants, surgical clips, probability of metal fragments, braces, or claustrophobia.",{"count":188,"type":20},240,[23],"The purpose of this clinical trial is to answer the question: can the investigators predict which adults with social anxiety disorder (SAD) will successfully respond to treatment? To answer this question, the investigators plan to recruit 190 adult participants who experience extreme forms of social anxiety to undergo brain imaging before and after 12 weeks of group cognitive behavioral therapy (CBT). Adults in the SAD group who do not respond enough to group CBT may be offered the opportunity to complete an additional 12 weeks of individual CBT while receiving SSRI medication (sertraline, see below) for SAD.\n\nData collected from participants who experience anxiety will be compared to a group of 50 participants with little or no social anxiety, who will serve as a comparison group.",[192],"Social Anxiety Disorder",[194,195,196,197,198,199,200,201,202,203,204],"social anxiety disorder","sertraline","exposure therapy","social cost","MRI","EEG","structural connectivity","functional connectivity","cognitive control system","positive valence system","negative valence system","2026-05-14",{"date":207,"type":32},"2026-05-18",{"date":209,"type":32},"2023-05-26",{"date":211,"type":20},"2027-06-30",{"name":38,"class":39},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":21,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":68},"100568696","telehealth-exercise-and-mindfulness-for-pain-in-osteoarthritis---stage-1b-100568696","NCT06684587","Telehealth Exercise and Mindfulness for Pain in Osteoarthritis - Stage 1B","Telehealth Exercise and Mindfulness for Pain in Osteoarthritis: A Stage 1B Feasibility Study","TEMPO-1B","Inclusion Criteria:\n\n* Meet National Institute for Health and Clinical Excellence clinical guidelines for knee osteoarthritis (i.e., age ≥ 50 years, presence of activity related pain, no morning knee stiffness or presence of morning knee stiffness ≤ 30 minutes)\n* BMI\\\u003C40\n* Knee pain on most days for 3 months or more\n* Average overall knee pain severity of ≥ 4 on an 11-point numeric rating scale over last 7 days, at least 2 weeks apart\n* Able to attend remote sessions\n* Can speak and understand English at a sufficient level to understand the study procedures and informed consent.\n* Available for study duration\n\nExclusion Criteria:\n\n* Contraindications to exercise\n* Other pain in lower back or legs that is greater than knee pain\n* Received physical therapy treatment for knee OA in the past 6 months or currently receiving physical therapy\n* Received any mindfulness programs such as Tai Chi, meditation, etc. in the past 6 months or currently receiving such program\n* Currently receiving chemotherapy or radiation therapy for cancer except non-melanoma skin cancer\n* History of other disease that may involve the index joint including inflammatory joint disease such as rheumatoid arthritis, seronegative spondyloarthropathy (eg, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease related arthropathy), crystalline disease (eg, gout or pseudogout), lupus erythematosus, knee joint infections, Paget's disease affecting the knee, or knee joint tumors.\n* Any knee surgery in the previous 6 months\n* Joint replacement in either hip or ankle\n* Previous knee osteotomy partial or total knee replacement in either knee\n* Planned major treatment for knee OA (e.g., surgery, injections, physical therapy) during the study period\n* Planned major surgery in the next 6 months\n* Corticosteroid or hyaluronic acid injections in either knee in the previous 3 months\n* Neurological conditions that impacts motor functioning (e.g., stroke, Parkinson's disease, Alzheimer's disease, Multiple Sclerosis, diabetic neuropathy, etc).\n* Pregnancy (self-report)\n* Participation in another clinical trial for any joint or muscle pain\n* Suspected or known drugs or alcohol abuse",{"count":222,"type":20},66,[23],"The goal of this randomized controlled trial (RCT) is to test the feasibility of an 10-week telehealth mindful exercise intervention compared to a telehealth exercise only intervention for people with knee osteoarthritis (OA). This RCT will be fully digital with all recruitment, assessments, and intervention being conducted remotely.",[226],"Knee Osteoarthritis",[228,229,230,231,232],"Telehealth","Exercise","Mindfulness","Pain","Feasibility","2026-04-30",{"date":235,"type":32},"2026-05-06",{"date":237,"type":32},"2025-04-24",{"date":239,"type":20},"2027-08",{"name":38,"class":39},{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":47,"sex":48,"minAge":248,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":40},"100472843","investigating-speech-sequencing-in-neurotypical-speakers-and-persons-with-disordered-speech-100472843","NCT05437159","Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech","Sequencing and Initiation in Speech Production: Investigating Speech Sequencing in Neurotypical Speakers, Persons Who Stutter, and Persons With Primary Progressive Aphasia","Inclusion Criteria\n\n* Healthy individuals with no history of neurological, speech, or hearing disorders (other than stuttering in studies that involve adults who stutter).\n* To maximize the uniformity of prior exposure to the speech stimuli that will be used, only native speakers of American English will be recruited, and only those with limited exposure to a second language will be enrolled.\n* All adult participants will also pass a standard pure-tone hearing screening at a 25dB hearing level threshold at 500, 1k, 2k, and 4kHz frequencies.\n* All participating children will pass a hearing screening at a 20 dB threshold at 500, 1k, 2k, and 4k Hz.\n* Participants in experiments that require them to read orthographic stimuli must have normal or corrected-to-normal vision (MRI-safe corrective glasses are available at the Boston University Cognitive Neuroimaging Center for use during neuroimaging).\n* Participating children will complete additional speech, language, hearing, and cognitive tests to ensure that they are within normal performance ranges for their age with the exception of stuttering for children in the children who stutter (CWS) group.\n* Persons who stutter will be evaluated formally by a speech-language pathologist to assess stuttering severity and to ensure the absence of other speech or language disorders. PWS will have no history of neurological disorder other than stuttering, and will demonstrate very mild to severe stuttering according to the Stuttering Severity Instrument for Children and Adults - 4th Edition (SSI-4: PRO-ED, Inc.), that is confirmed by clinical reports and expressed concern by the subject and\u002For guardian.\n* Participants with primary progressive aphasia (PPA) will have been diagnosed through the Massachusetts General Hospital Frontotemporal Disorders Unit (MGH-FTD) by an experienced neurologist in coordination with a speech-language pathologist.\n* Participants with PPA will have a score of 1.0 or lower on the Clinical Dementia Rating scale (i.e., mild cognitive impairment or mild dementia) to ensure cognitive levels are sufficient to complete the task.\n* All participants with PPA must have a recent clinical assessment and T1 structural neuroimaging scan through the MGH-FTD Unit for eligibility for this study.\n\nExclusion Criteria\n\n* Participants in studies that involve tDCS or MRI scanning will have no contraindications specific to those procedures. For the tDCS study, this includes individuals who have a metallic implant in the head or electrically sensitive devices implanted in the body, a history of seizures, significant scalp lesions, or pregnancy.\n* For MRI studies, this includes a history of seizures, severe claustrophobia, the presence of magnetically or mechanically active implant, ferromagnetic material embedded in any part of the body, or pregnancy).\n* All participants will perform a standardized nonword repetition pre-test (the Dollaghan and Campbell Nonword Repetition Task) to assess working memory performance. Participants who perform more than 2 standard deviations below the norm for their age range will be deemed to be unable to perform the experimental task and released from further participation.\n* Participating children will have no history of neurological disorder other than stuttering, and will demonstrate very mild to severe stuttering according to the Stuttering Severity Instrument for Children and Adults, 4th Edition, that is confirmed by clinical reports and expressed concern by the subject and\u002For guardian.\n* Children under the age of 6 and over the age of 8 will not enrolled in this study.\n* Participants with PPA will not be eligible for this study if they are taking any medications that would be expected to affect speech or language.","6 Years",{"count":95,"type":20},[23],"Persistent developmental stuttering affects more than three million people in the United States, and it can have profound adverse effects on quality of life. Despite its prevalence and negative impact, stuttering has resisted explanation and effective treatment, due in large part to a poor understanding of the neural processing impairments underlying the disorder. The overall goal of this study is to improve understanding of the brain mechanisms involved in speech motor planning and how these are disrupted in neurogenic speech disorders, like stuttering. The investigators will do this through an integrated combination of experiments that involve speech production, functional MRI, and non-invasive brain stimulation. The study is designed to test hypotheses regarding the brain processes involved in learning and initiating new speech sound sequences and how those processes compare in persons with persistent developmental stuttering and those with typical speech development. These processes will be studied in both adults and children. Additionally, these processes will be investigated in patients with neurodegenerative speech disorders (primary progressive aphasia) to further inform the investigators understanding of the neural mechanisms that support speech motor sequence learning. Together these experiments will result in an improved account of the brain mechanisms underlying speech production in fluent speakers and individuals who stutter, thereby paving the way for the development of new therapies and technologies for addressing this disorder.",[253,254],"Stuttering, Developmental","Aphasia, Primary Progressive",[253,256,257,258,259,260],"Magnetic Resonance Imaging","Transcranial Direct Current Stimulation","Speech Motor Learning","Speech Disorders","Neurocomputational Modeling","2026-04-28",{"date":263,"type":32},"2026-05-04",{"date":265,"type":32},"2023-04-03",{"date":267,"type":20},"2026-05",{"name":38,"class":39},{"id":270,"slug":271,"hasResults":12,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":4,"eligibilityCriteria":275,"healthyVolunteers":12,"sex":48,"minAge":49,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":21,"phases":279,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":286,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":4},"100634240","effects-of-music-during-walking-on-pain-and-muscle-activation-in-people-with-chronic-pain-due-to-knee-osteoarthritis-100634240","NCT07537114","Effects of Music During Walking on Pain and Muscle Activation in People With Chronic Pain Due to Knee Osteoarthritis","Effects of Music-Based Rhythmic Auditory Stimulation During Walking on Nociceptive Signaling and Muscle Activation in People With Chronic Pain Due to Knee Osteoarthritis","Inclusion Criteria:\n\n* Have activity related pain\n* Experience morning knee stiffness ≤ 30 minutes\n* Knee pain on most days for 3 months or more\n* Able to walk at least 20 minutes with assistance\n* Average overall knee pain severity of ≥= 4 on a 11-point numeric rating scale during previous week\n* BMI ≤ 40\n* Able to communicate using English at a level to understand the study procedures and informed consent\n\nExclusion Criteria:\n\n* Contraindications to exercise\n* Joint replacement in either hip, knee, or ankle\n* History of other disease that may involve the index joint including inflammatory joint disease such as rheumatoid arthritis, seronegative spondyloarthropathy (eg, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel disease related arthropathy), crystalline disease (eg, gout or pseudogout), lupus erythematosus, knee joint infections, Paget's disease affecting the knee, or knee joint tumors.\n* Previous knee osteotomy in either knee\n* Other health conditions that impact motor functioning or prevent participation (e.g., stroke, Parkinson's disease, Alzheimer's disease, Multiple Sclerosis, diabetic neuropathy, etc.)\n* Corticosteroid or hyaluronic acid injections in either knee in the previous 3 months\n* Pregnancy (self-report)\n* Suspected or known drugs or alcohol abuse\n* Mini-mental State Examination (MMSE) score \\\u003C 24\n* Hearing impairments\n* Pain in lower back or legs that is greater than knee pain","85 Years",{"count":278,"type":20},20,[23],"The purpose of this research study is to compare muscle activation, changes in pain sensitivity, and brain function, between different walking conditions, including walking to music, walking to metronome, and walking without music or metronome.",[226],[283,284,285],"music","rhythmic auditory stimulation","knee pain","NOT_YET_RECRUITING","2026-04-17",{"date":289,"type":32},"2026-04-22",{"date":291,"type":20},"2026-08",{"date":293,"type":20},"2027-07",{"name":38,"class":39},{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":47,"sex":48,"minAge":302,"maxAge":4,"enrollmentInfo":303,"targetDuration":4,"studyType":21,"phases":304,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":286,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100628434","early-phase-1-memory-enhancement-in-aging-with-optimal-dosing-100628434","NCT07461584","Memory Enhancement in Aging With Optimal Dosing","Personalized Memory Enhancement in Aging: Pattern-Optimized tACS With Closed-Loop Precision Modulation","Inclusion Criteria:\n\n* 65 years of age or older\n* normal or corrected-to-normal vision\n* color vision\n\nExclusion Criteria:\n\n* pregnant\n* metal implants in head\n* implanted electronic devices\n* history of neurological problems or head injury\n* skin sensitivity\n* claustrophobia\n* dementia (normal Montreal Cognitive Assessment \\> 25)\n* depression (normal Geriatric Depression Scale \\\u003C 10)\n* history of psychosis\n* cognitive deficits (MoCA\\>25)\n* any psychoactive medication","65 Years",{"count":188,"type":20},[305],"EARLY_PHASE1","This project optimizes high-resolution tACS to improve memory in healthy older adults, advancing drug-free approaches for ADRD. We test stimulation schedules and develop an adaptive, brain-guided tACS system to strengthen memory-supporting networks.",[308,309,310],"Aging","Noninvasive Brain Stimulation","Memory","2026-04-01",{"date":313,"type":32},"2026-04-07",{"date":315,"type":20},"2026-05-01",{"date":317,"type":20},"2031-01-31",{"name":38,"class":39},{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":47,"sex":48,"minAge":17,"maxAge":49,"enrollmentInfo":326,"targetDuration":4,"studyType":21,"phases":328,"briefSummary":329,"conditions":330,"keywords":333,"overallStatus":286,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":68},"100628297","investigating-individual-differences-in-speech-motor-skills-in-neurotypical-speakers-and-persons-with-disordered-speech-100628297","NCT07459803","Investigating Individual Differences in Speech Motor Skills in Neurotypical Speakers and Persons With Disordered Speech","Brain Mechanisms Underlying Neurotypical and Disordered Speech","Inclusion Criteria:\n\n* Native speakers of American English\n* Adults age 18-50\n* Age-appropriate cognitive and receptive vocabulary skills\n* Age-appropriate hearing\n* Adults with dyslexia will have a history of dyslexia or report of ongoing reading difficulties that will be confirmed at the first screening visit\n* Adults who stutter will have a history of stuttering that will be confirmed at the first screening visit\n\nExclusion Criteria:\n\n* History of neurological disorder, including a history of seizures\n* Major brain injury, brain surgery, or stroke\n* Orthodontia or atypical oral structure (e.g., cleft palate) that interferes with speech\n* Fluency disorder (except those in the persons who stutter cohort), apraxia of speech, or dysarthria\n* Language or reading disorder (except those in persons with dyslexia cohort)\n* Standardized score below 80 on the Kaufman Brief Intelligence Test\n* Standardized score below 1 standard deviation on the NIH Toolbox Picture Vocabulary Test\n* Pregnancy\n* Severe claustrophobia\n* Presence of magnetically or mechanically active implant, or other ferromagnetic material embedded in any part of the body\n* Significant scalp lesions that would prevent transcranial direct stimulation",{"count":327,"type":20},90,[23],"This study aims to understand how people use different types of feedback to control their speech. When an individual speaks, the brain relies on several systems at the same time, such as sensory systems that monitor an individuals own voice and the movements of their speech muscles, and a motor system that builds and reads out learned motor patterns. The investigators are studying how these systems work together and how they differ across individuals.\n\nInvestigators will test 90 adults between 18 and 50 years old, including people who stutter, people with dyslexia, and people with typical speech and reading development. Participants will complete several short speech tasks in which the sounds they hear or the movements of their jaw or larynx are briefly changed. These responses will be used to measure each person's speech motor skills and to estimate the settings of a computer model called \"SimpleDIVA,\" which simulates how the brain controls speech.\n\nParticipants will also complete an MRI scan so investigators can measure the structure and connectivity of different brain regions. These measures will help investigators understand how individual differences in the brain relate to the speech motor control skills we observe. Participants will also complete sessions with noninvasive brain stimulation (transcranial current stimulation, or tCS) to examine how stimulation of specific areas of the brain affects responses during the speech tasks.\n\nThe knowledge gained from this study will help researchers understand why speech motor skills vary across people and how differences in neural function may contribute to conditions such as stuttering and dyslexia.",[253,331,332],"Dyslexia","Healthy Participants",[334,256,258,259,260,331],"Stuttering Developmental","2026-03-10",{"date":337,"type":32},"2026-03-12",{"date":339,"type":20},"2026-04",{"date":341,"type":20},"2030-03",{"name":38,"class":39},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":21,"phases":350,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":95},"100627986","investigating-subcortical-contributions-to-speech-sequencing-in-deep-brain-stimulator-recipients-100627986","NCT07455760","Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients","Inclusion Criteria:\n\n* Native speakers of American English\n* Adults at least 18 years of age\n* A clinically established diagnosis of Parkinson's disease or essential tremor\n* Able to provide informed consent in the judgment of the investigator\n* Treated with deep brain stimulation of the subthalamic nucleus (Parkinson's disease) or ventral intermediate nucleus of the thalamus (essential tremor)\n* Stable Parkinson's disease or essential tremor medication regimen for at least one month\n* Stable DBS program settings for at least one month\n* Nominal DBS system function, including normal impedances at therapeutic DBS contacts, and adequate battery life or adequate IPG charging status for therapy\n* For DBS sensing, implanted with Medtronic Percept PC or Percept RC implantable pulse generator\n* Corrected vision adequate to easily read text presented during speech motor task\n\nExclusion Criteria:\n\n* Cognitive impairment (Montreal Cognitive Assessment (MoCA; Nesreddine et al., 2005) score \\\u003C 25) or active psychotic or behavioral symptoms that would, in the judgment of the investigator, preclude proper participation in the study\n* Hearing impairment that interferes with accurate perception of the speech motor learning stimulus (25dB hearing level threshold at 500, 1k, 2k, and 4kHz frequencies)\n* Language impairment (aphasia) or speech articulation impairment (dysarthria) that precludes performance of the speech motor learning task\n* Neurological disorder that interferes with speech motor learning\n* Inability to tolerate symptoms when DBS is off\n* Orthodontia or atypical oral structure (e.g., cleft palate) that interferes with speech\n* Pregnancy\n* For participants in the sub-syllabic sequence learning study (Study C.2.1), experience with the following languages: Hebrew, Polish, Lithuanian, Romanian, Georgian, Tepehua, Hungarian, and Pima",{"count":19,"type":20},[23],"This study will examine how two important brain circuits - one involving the subthalamic nucleus (STN) and one involving the ventral intermediate nucleus of the thalamus (VIM) - contribute to learning and producing speech sequences. Participants will include two groups: 1. individuals with Parkinson's disease who have deep brain stimulation (DBS) devices targeting the STN and 2. individuals with essential tremor who have DBS devices targeting the VIM.\n\nParticipants will complete speech tasks involving the learning and repetition of novel sound sequences. During some parts of the study, DBS stimulation will be temporarily turned on or off in a controlled research setting. This will allow researchers to examine how stimulation affects both the learning of new speech sequences and the production of previously learned sequences. All STN participants and most VIM participants will also be equipped with a cutting-edge DBS system, the Percept PC, which will enable the recording of deep brain activity during the tasks.\n\nThe results of this study will improve our understanding of how different brain circuits support speech learning and production. In particular, this study will help to differentiate the roles of the STN and VIM in learning the ordering of speech sounds within a syllable from learning of speech sequences containing multiple syllables. This knowledge may help guide future approaches to optimizing DBS settings to improve both movement and speech outcomes in individuals with neurological disorders, as well as provide greater general insight into how these brain structures contribute to speech production and learning.",[353,354],"Parkinson's Disease (PD)","Essential Tremor",[356,357,354,259,260,358],"Deep Brain Stimulation","Parkinson's Disease","Stuttering","2026-03-06",{"date":361,"type":32},"2026-03-09",{"date":363,"type":32},"2026-02-18",{"date":365,"type":20},"2030-08",{"name":38,"class":39},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":47,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":374,"targetDuration":4,"studyType":21,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":286,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":4},"100608958","early-phase-1-restructuring-the-alpha-gamma-code-in-aging-vision-100608958","NCT07208318","Restructuring the Alpha-Gamma Code in Aging Vision","Rescuing Visual Perception in Aging Adults by Restructuring the Alpha-Gamma Neural Code","Inclusion Criteria:\n\n* 18+ years of age or older\n* normal or corrected-to-normal visual acuity, color vision, and stereo vision\n\nExclusion Criteria:\n\n* not pregnant,\n* no metal implants in head,\n* no implanted electronic devices,\n* no history of neurological problems or head injury,\n* no skin sensitivity,\n* no claustrophobia,\n* no dementia (normal Mini Mental State Examination between 24-30; Montreal Cognitive Assessment \\> 25)\n* no depression (normal Beck Depression Inventory II \\\u003C13; Geriatric Depression Scale \\\u003C 10)\n* no ophthalmological diseases (e.g., strabismus, glaucoma, cataract, macular degeneration)\n* no history of psychosis\n* no cognitive deficits (MMSE score\\>24; MoCA\\>25)\n* cannot be taking any psychoactive medication.",{"count":188,"type":20},[305],"Tests whether age-related visual deficits arise from disrupted alpha-gamma coupling in visual cortex (V1) and MT. Uses fMRI, source-resolved HD-EEG, and personalized complex-waveform HD-tACS to (1) quantify aging effects on phase-amplitude coupling, (2) drive PAC into a preferred \"gamma-at-alpha-troughs\" state, and (3) bidirectionally change perception by aligning gamma to alpha troughs vs peaks. Two five-day, double-blind, sham-controlled studies (n=120 each) target contrast sensitivity (V1) and 3D shape-from-motion (MT), aiming for mechanistic insight and remediation in older adults with implications for ADRD.",[308,378,309],"Visual Perception","2025-09-27",{"date":381,"type":32},"2025-10-06",{"date":383,"type":20},"2026-01-10",{"date":385,"type":20},"2030-08-31",{"name":38,"class":39},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":47,"sex":48,"minAge":17,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":21,"phases":396,"briefSummary":397,"conditions":398,"keywords":400,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":68},"100459260","improving-spatial-perception-and-speech-understanding-in-multitalker-mixtures-100459260","NCT05260307","Improving Spatial Perception and Speech Understanding in Multitalker Mixtures","Inclusion Criteria: Normal-Hearing Subjects\n\n* 18 to 35 years of age\n* Audiometric thresholds that do not exceed 20 dB HL at any frequency from 250 to 8000 Hz\n* Able to provide informed consent and understand experimental instructions\n* Normal or corrected-to-normal vision\n\nInclusion Criteria: Hearing-Impaired Subjects\n\n* 18 to 80 years of age\n* Documented sensorineural hearing loss\n* Able to provide informed consent and understand experimental instructions\n* Normal or corrected-to-normal vision\n\nExclusion Criteria (some experiments)\n\n* Non-native speakers of English","80 Years",{"count":395,"type":20},220,[23],"The purpose of this study is to investigate several approaches for improving spatial perception and speech intelligibility in multitalker listening situations for hearing-aid users. The hypotheses are that spatial perception and speech intelligibility will be improved by (1) increased high-frequency audibility, (2) speech envelope enhancement, and\u002For (3) appropriate sound image externalization.",[399],"Hearing Loss",[401,402,403,404,405,406,407],"Hearing Aids","Speech Intelligibility","Spatial Hearing","Cocktail Party","Audibility","Sound Image Externalization","Speech Envelope","2025-09-19",{"date":410,"type":32},"2025-09-24",{"date":412,"type":32},"2022-03-09",{"date":414,"type":20},"2026-11-30",{"name":38,"class":39},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":47,"sex":48,"minAge":49,"maxAge":423,"enrollmentInfo":424,"targetDuration":4,"studyType":21,"phases":426,"briefSummary":427,"conditions":428,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":68},"100523323","improving-memory-in-alzheimers-disease-with-noninvasive-brain-stimulation-100523323","NCT06094192","Improving Memory in Alzheimer's Disease With Noninvasive Brain Stimulation","Personalized Synchronization of Cortical Rhythms to Improve Memory in Alzheimer's Disease","All subjects. Age 50-100 years. We will equally recruit subjects with respect to gender, race, ethnicity, socioeconomic and other factors to allow the results of this research to yield the greatest generalizability.\n\nMild AD dementia. Meets probable AD dementia NIA-AA criteria 86; MoCA 10-25 85; performance on Uniform Data Set version 3 (UDS-3) delayed recall (Craft Story 21) and recognition (Benson Complex Figure) memory worse than 1.5 SD for age and education; worse than 1.5 SD for age and education in at least one other cognitive domain (e.g., language, executive functioning) based on other tests in the UDS-3. A summary of the NIA-AA criteria for AD dementia are that the patient has (1) dementia, such that cognitive or behavioral symptoms (a) are interfering with the ability to function at work or usual activities, (b) represent a decline from previous level of functioning, (c) are not explained by delirium or major psychiatric disorder, (d) are detected and diagnosed, and (e) involve a minimum of two domains including memory, executive function, visuospatial abilities, language, and personality or behavior or comportment; (2) insidious onset; (3) clear-cut history of worsening of cognition; (4) prominent cognitive deficits by history and examination from either (a) an amnestic presentation or (b) a non-amnestic presentation, which can be a language, visuospatial, or executive dysfunction presentation; and lastly (5) no (a) substantial concomitant cerebrovascular disease, (b) core features of Dementia with Lewy Bodies, (c) prominent features of behavioral variant frontotemporal dementia (FTD), (d) prominent features of primary progressive aphasia, or (e) evidence for another concurrent, active disorder or use of medication that could have a substantial effect on cognition. All diagnoses are made by the BU ADRC clinical core consensus and confirmed by Dr. Budson. The majority of patients will have a positive AD biomarker, either from cerebrospinal fluid (CSF) or positron emission tomography (PET). See also Additional Inclusion\u002FExclusion criteria below.\n\nMCI due to AD. Meets MCI due to AD according to NIA-AA criteria 86; MoCA \\>18 85; performance on Uniform Data Set version 3 (UDS-3) delayed recall (Craft Story 21) and recognition (Benson Complex Figure) memory worse than 1.0 SD for age and education adjusted norms. A summary of the NIA-AA criteria for MCI due to AD are that there is (1) clinical concern reflecting a change in cognition reported by patient, informant, or clinician; (2) objective impairment in one or more domains, typically including memory; (3) preservation of independence in functional abilities; (4) not demented; (5) a rule out of vascular, traumatic, and medical causes of cognitive decline; (6) evidence of longitudinal decline in cognition, when feasible; (7) history consistent with AD genetic factors, where relevant. All diagnoses are made by the BU ADRC clinical core consensus and confirmed by Dr. Budson. The majority of patients will have a positive AD biomarker, either from CSF or PET. See also Additional Inclusion\u002FExclusion criteria below.\n\nHealthy controls. Healthy controls will also be recruited from the BU ADRC and will be age, education, and gender matched to the AD patients. They will have a MoCA \\> 2585 and performance within 1.0 SD for age and education adjusted norms on Uniform Data Set version 3 (UDS-3). All \"diagnoses\" of healthy controls will be made by the BU ADRC clinical core consensus and confirmed by Dr. Budson. The majority of healthy controls will have a negative AD biomarker, either from CSF or PET. See also Additional Inclusion\u002FExclusion criteria below.\n\nAll subjects. Current conditions allowed: mild depression and\u002For anxiety not requiring hospitalization or medications other than what are listed below; hyperlipidemia; hypercholesterolemia; hypertension; heart disease; asthma; gastroesophageal reflux disease; edema; treated hypothyroidism; systemic vascular disease (but not stroke); dermatological disorders; ophthalmologic disorders. Prior conditions excluded: stroke, traumatic brain injury, other brain or systemic disorder that, in the opinion of Dr. Budson, has produced a permanent alteration of cognition. Current medications allowed: selective serotonin reuptake inhibitors; cholinesterase inhibitors (for the patients with AD); statins; beta adrenergic blockers; bronchodilators; ace inhibitors; calcium channel blockers; angiotensin II receptor blockers; other antihypertensive agents; histamine-2 receptor antagonists; proton-pump inhibitors; diuretics; thyroid medications; aspirin; non-narcotic analgesics; antiplatelet agents; vitamins \\& minerals; topical medications; eye drops.\n\nInclusion\u002Fexclusion criteria related to tasks, EEG and tACS. Subjects must have normal or corrected-to-normal vision, color vision, nonpregnant, no metal implants in head, no implanted electronic devices, no skin sensitivity, and no claustrophobia.\n\nAdditional exclusion criteria. Subjects will be excluded if they cannot understand the informed consent or the experimental procedures. Subjects will be excluded if they have a significant vision and\u002For hearing impairment which will prevent them from understanding the informed consent and from completing the experimental procedures.","100 Years",{"count":425,"type":20},204,[23],"The investigators will evaluate the theory that Alzheimer's disease-related memory impairment derives from the inefficient orchestration of rhythmic activity at the level of large-scale cortical networks. The results as expected to elucidate AD-related pathophysiology and set groundwork for the development of drug-free interventions for improving memory in AD and related dementias.",[429],"Alzheimer Disease","2025-09-15",{"date":408,"type":32},{"date":433,"type":32},"2023-12-20",{"date":435,"type":20},"2028-05-31",{"name":38,"class":39},{"id":438,"slug":439,"hasResults":12,"nctId":440,"briefTitle":441,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":47,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":21,"phases":444,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":68},"100515634","neuromodulation-for-a-novel-ocd-biomarker-and-treatment-100515634","NCT05994053","Neuromodulation for a Novel OCD Biomarker and Treatment","Inclusion Criteria:\n\n(1) a primary DSM-5 diagnosis of OCD, (2) a score of 16 or greater on the YBOCS (3) at least 18 years of age; and (4) willingness and ability to provide informed consent and comply with the requirements of the study protocol.\n\nExclusion Criteria:\n\n(1) a lifetime history of bipolar or psychotic disorders; (2) history of Tourette syndrome; (3) psychosurgery; (4) substance abuse or dependence (other than nicotine) in the past 3 months; (5) organic brain syndrome, mental retardation or other potentially interfering cognitive dysfunction; (6) severe depression (MADRS score of 30 or greater); (7) suicidal risk as determined by moderate or greater score on the Columbia Suicide Severity Rating Scale (C-SSRS); (8) pregnancy or lactation; (9) changes to pharmacotherapy for OCD or the initiation of cognitive-behavior therapy within the last 3 months; and (10) specific to the tACS and EEG procedures no metal implants in head, any implanted electronic devices, any skin sensitivity, color blindness or impaired vision despite correction, claustrophobia, and any history of epilepsy or neurological disorder.",{"count":327,"type":20},[23],"Although multiple treatments for OCD exist, slow symptom decrease, high remission, and significant side effects for some OCD patients limit their efficacy. More research into the precise neural mechanisms and linked cognitive functions in OCD is also necessary. To address both concerns, this study by Dr. Reinhart and his team will test a new, non-invasive, and well-tolerated neuromodulation method for reducing OCD symptoms, based on reward-related rhythms of the orbitofrontal cortex (OFC; a brain region responsible for reward, decision making and other crucial functions that is affected by OCD). This proposal is based on highly encouraging preliminary data in both subsyndromal and treatment-resistant populations that shows rapid reductions in OCD behaviors that last at least 1-3 months. Using high-definition transcranial alternating current stimulation (HD-tACS) guided by EEG brain wave recordings, the study will test whether repetitive modulation of relevant rhythm activity in the OFC can lead to rapid (within five days) and sustainable (up to three months) OCD symptom reduction. This research aims to increase knowledge of OCD and development of effective treatment with minimal side effects.",[447],"OCD",{"date":449,"type":32},"2025-09-17",{"date":451,"type":32},"2024-07-01",{"date":453,"type":20},"2026-08-31",{"name":38,"class":39},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":47,"sex":48,"minAge":4,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":21,"phases":465,"briefSummary":466,"conditions":467,"keywords":469,"overallStatus":286,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":68},"100602868","assessing-the-performance-of-7-day-vs-1-day-packaging-for-small-quantity-lipid-based-nutrient-supplements-in-ghana-sqlns7d-1d-comparison-100602868","NCT07129109","Assessing the Performance of 7-Day vs 1-Day Packaging for Small Quantity Lipid-Based Nutrient Supplements in Ghana (SQLNS:7D-1D Comparison)","Assessing the Performance of 7-Day vs 1-Day Packaging for Small Quantity Lipid-Based Nutrient Supplements in Ghana (SQLNS:7Dv1D Comparison)","SQLNS:7Dv1D","Inclusion Criteria:\n\n* Primary caregiver of a child aged 6-24 months attending growth monitoring and promotion (GMP) services at one of the participating health facilities\n* Willing and able to provide informed consent\n* Plans to remain in the area for the duration of the study period\n* Agrees to participate in surveys and\u002For interviews related to supplement use\n\nExclusion Criteria:\n\n* Caregiver of a child with a diagnosed severe illness requiring hospitalization\n* Caregiver under the age of 18",{"count":464,"type":20},500,[23],"This cluster-randomized crossover trial evaluates the impact of two different packaging formats for small-quantity lipid-based nutrient supplements (SQ-LNS) on adherence and acceptability among caregivers of young children in Northern Ghana. SQ-LNS are a proven intervention for reducing child malnutrition, but optimizing packaging formats may improve adherence and scalability.\n\nEight health facilities participating in growth monitoring services will each receive both formats: a 1-day sachet (20g daily) and a 7-day bulk container (140g weekly), with the order of delivery randomized. Each packaging format will be distributed for one month before cross-over. The primary outcomes are adherence (measured through caregiver self-report and sachet counts) and acceptability (assessed via caregiver interviews). Secondary outcomes include caregiver preference, ease of use, and qualitative insights into feeding practices, beliefs, and packaging usability.\n\nThis implementation research study uses a convergent mixed-methods design, integrating quantitative adherence and acceptability data with in-depth interviews and structured observations to inform real-world program implementation. Findings will guide policy and program decisions for integrating SQ-LNS into child health platforms in Ghana and other low-resource settings.",[468],"Child Malnutrition",[470,471,472,473],"Small-quantity lipid-based nutrient supplments (SQ-LNS)","Ghana","Infant and young child feeding","Growth monitoring and promotion (GMP)","2025-08-11",{"date":476,"type":32},"2025-08-19",{"date":478,"type":20},"2026-01",{"date":480,"type":20},"2026-03",{"name":38,"class":39},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":488,"eligibilityCriteria":489,"healthyVolunteers":12,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":21,"phases":491,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":68},"100554039","positive-minds-strong-joints-for-knee-osteoarthritis-100554039","NCT06493903","Positive Minds Strong Joints for Knee Osteoarthritis","Physical and Mental Health Intervention for Black Adults With Knee Osteoarthritis: A Feasibility Study","PMSJ","INCLUSION CRITERIA:\n\n* Age≥50\n* BMI ≤ 40 kg\u002Fm2\n* Self-identify as Black (including African American)\n* Knee pain ≥4\u002F10 on a 11 numeric scale over the past week\n* Scored 5 or more on either the Patient Health Questionnaire (PHQ-9) and\u002For the Generalized Anxiety Disorder 7-item Scale (GAD-7)\n* Can speak and understand English at a sufficient level to understand the study procedures and informed consent\n* Available for study duration\n* Able to attend remote sessions\n\nEXCLUSION CRITERIA\n\n* Knee, hip or ankle replacement\n* Intra-articular corticosteroid or hyaluronic acid knee injection within 3 months\n* Knee surgery within past 6 months\n* Currently receiving or received within 3-months any PT for knee OA\n* Currently receiving or received within 3 months any mental health intervention (excluding pharmacologic treatments)\n* Planning to initiate physical therapy for joint or low back pain in the next 3months\n* Planning to initiate any mental health treatment (excluding pharmacologic treatments) in the next 1 month.\n* Systemic inflammatory arthritis (e.g., rheumatoid arthritis)\n* Neurologic conditions (e.g., stroke, Parkinson's disease, etc.)\n* Contraindications to starting an exercise program.\n* Suspected substance abuse\n* Lack capacity to consent\n* Pregnancy (self-report)\n* Participation in another clinical trial for any joint or muscle pain\n* Planning for a major surgery in the next 6 months\n* Having high risk mental health symptoms (active suicidality, bipolar disorder, mania, psychosis, schizophrenia)\n* Receiving chemotherapy or radiation therapy for cancer (except non-melanoma skin cancer)",{"count":52,"type":20},[23],"The aim of this research study is to test the feasibility of a physical and mental health intervention (Positive Minds, Strong Joints or PMSJ) for Black adults with knee osteoarthritis (OA).",[494],"Osteoarthritis, Knee",[496,497,498,499,500,501],"chronic pain","depression","anxiety","exercise","cognitive behavioral therapy","Black adults","2025-05-13",{"date":504,"type":32},"2025-05-16",{"date":506,"type":32},"2025-02-17",{"date":508,"type":20},"2026-12-30",{"name":38,"class":39},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":48,"minAge":4,"maxAge":517,"enrollmentInfo":518,"targetDuration":4,"studyType":21,"phases":520,"briefSummary":521,"conditions":522,"keywords":524,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":68},"100532980","harness-based-mobility-intervention-for-infants-with-down-syndrome-100532980","NCT06219863","Harness-based Mobility Intervention for Infants With Down Syndrome","Feasibility and Outcome Measures for Infants With Down Syndrome: Advancing Clinical Trial Readiness for a Harness-based Mobility Intervention","Inclusion Criteria:\n\n* confirmed diagnosis of Trisomy 21\n* younger than 24 months\n* English is the primary language of the home (due to use of standardized language assessments normed on English-speaking children)\n* able to sit without support\n* not yet taking any independent steps.\n\nExclusion Criteria:\n\n* Mosaic or Translocation Down syndrome\n* severe, uncontrolled medical problems (including heart disease with cardiovascular instability, uncontrolled epilepsy)\n* severe uncorrected hearing or vision impairments","2 Years",{"count":519,"type":20},6,[23],"The emergence of crawling and walking is significantly delayed in infants with Down syndrome (DS), but the development of independent mobility provides infants with new opportunities for exploring the environment and interacting with objects and people that are important foundations for early learning. Increasing infant mobility early in development with body weight supported harness systems may support infant exploration, communication, and social interaction. This project will set the stage for the first clinical trial of a mobility-related intervention specifically tailored for infants with DS by testing the feasibility of harness systems with infants and families and identifying measures that will serve as primary outcome variables. Upon completion of this pilot project, necessary preliminary data and experience required for an in-home, high-impact clinical trial for infants with DS will have been obtained.",[523],"Down Syndrome",[525],"infant","2025-05-11",{"date":528,"type":32},"2025-05-14",{"date":530,"type":32},"2024-07-31",{"date":532,"type":20},"2025-09-30",{"name":38,"class":39},{"id":535,"slug":536,"hasResults":12,"nctId":537,"briefTitle":538,"officialTitle":539,"acronym":540,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":21,"phases":544,"briefSummary":545,"conditions":546,"keywords":549,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":95},"100588395","a-pilot-randomized-controlled-trial-of-the-hopeful-and-healthy-living-program-100588395","NCT06940843","A Pilot Randomized Controlled Trial of the Hopeful and Healthy Living Program","Enhancing Social Connection, Health, and Aging in Older Persons: A Pilot Randomized Trial of the Hopeful and Healthy Living (HHL) Program","(HHL)","Inclusion Criteria:\n\n50 years or older, diagnosis of a serious mental illness, and a member of Center Club or Transitions of Boston\n\nExclusion Criteria:\n\nDiagnosis of dementia or other progressive neurological disorder",{"count":543,"type":20},60,[23],"The goal of this clinical trial is to learn if a novel psychosocial intervention is effective in helping adults over 50 with serious mental illness (SMI) increase their social connections and participate in more healthy lifestyle activities. The Hopeful and Healthy Living (HHL) intervention combines social skills training and training in cognitive self-management strategies in order to help older adults build healthy lifestyle and social routines. We predict that:\n\n* Individuals who participate in the HHL intervention will improve more in perceived social support (i.e., what people get from relationships such as reliance, reassurance of worth, attachment) and loneliness at the 4-, 8-, and 12-month follow-up assessments than those who receive treatment as usual (TAU).\n* Individuals who participate in the HHL intervention will improve more in overall psychosocial functioning at the 4-, 8-, and 12-month follow-up assessments than those who receive TAU.\n* Individuals who participate in the HHL intervention will improve more in cognitive functioning at the 4-, 8-, and 12-month follow-up assessments than those who receive TAU.\n* Individuals who participate in the HHL intervention will improve more in healthy behaviors (sleep, activity, diet) at the 4-, 8-, and 12-month follow-up assessments than those who receive TAU.\n\nIn this trial, participants will be either receive the HHL intervention or participate in their regular treatment activities (treatment as usual). HHL vs. TAU will be compared to see if there are any differences in social support, cognition, loneliness, psychosocial functioning, or healthy lifestyle activities including physical activity, sleep, and diet.\n\nParticipants will be asked to complete an interview-based assessment at baseline, 4-months, 8-months, and 12-months. After completing the baseline assessment, those who are in the experimental group will participate in the 16-week long HHL group intervention.",[547,548],"Serious Mental Illness","Older Adults",[550,551,552,553,554],"psychosocial interventions","cognitive interventions","social skills interventions","healthy lifestyle interventions","older adults with SMI","2025-04-23",{"date":557,"type":32},"2025-04-25",{"date":559,"type":32},"2025-03-12",{"date":561,"type":20},"2028-07-31",{"name":38,"class":39},{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":21,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":68},"100431277","initial-assessment-of-the-feasibility-and-efficacy-of-a-scalable-digital-cbt-for-generalized-anxiety-and-associated-health-behaviors-in-a-cardiovascular-disease-population-100431277","NCT04895995","Initial Assessment of the Feasibility and Efficacy of a Scalable Digital CBT for Generalized Anxiety and Associated Health Behaviors in a Cardiovascular Disease Population","Inclusion Criteria:\n\n* Experienced an acute CVD event (i.e., myocardial infarction, stroke\u002Ftransient ischemic attack, cardiac arrest, unstable angina, congestive heart failure with hospitalization; exclusion of coronary heart disease, atrial fibrillation, and other arrhythmias)\n* Clinical levels of GAD symptoms as operationalized by a score of ≥10 on the GAD-7\n* Age 18 or older.\n* Individuals must be in the post-acute phase of their CVD; this is operationalized as \\> 2 months post an acute cardiac event.\n\nExclusion Criteria:\n\n* Non-English speaker\u002Fliterate\n* No access to a digital device\n* Severely vision impaired\n* Severe cognitive impairment\n* Pending acute surgery or with a life prognosis of fewer than 6 months\n* The presence \\[by self-report\\] of schizophrenia, psychosis, bipolar disorder, seizure disorder, or current substance use disorder other than nicotine\n* Initiation or change of psychotropic medication dosage within the past 4 weeks\n* Received CBT for anxiety in last 3 months",{"count":570,"type":20},95,[23],"The treatment of generalized anxiety disorder (GAD) in an accessible manner represents an unmet need for those with cardiovascular disease (CVD), given that patients with CVD experience numerous barriers for in-person treatment engagement. The research plan for the proposed pilot project will entail: (1) open study of the acceptability of the digital intervention (N=5), followed by (2) recruitment and randomization of 90 individuals with a history of acute CVD events and clinical levels of GAD symptoms to dCBT or a waitlist (Control) condition, using a 1.5:1 allocation (dCBT:Control).",[574,575,576,577],"Anxiety Disorders","Cardiovascular Diseases","Anxiety","Health Behavior","2025-03-13",{"date":580,"type":32},"2025-03-14",{"date":582,"type":32},"2022-02-02",{"date":584,"type":20},"2026-03-15",{"name":38,"class":39},{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":48,"minAge":17,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":21,"phases":594,"briefSummary":595,"conditions":596,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":601,"leadSponsor":603,"locationsCount":68},"100470476","neural-mechanisms-of-spatial-representations-beyond-the-self-100470476","NCT05406349","Neural Mechanisms of Spatial Representations Beyond the Self","Inclusion Criteria:\n\n* Between 18 and 70 years of age\n* Adequate visual and auditory acuity to allow neuropsychological testing\n* Have undergone depth electrode placement for the purpose of epilepsy evaluation\u002Ftreatment OR have NeuroPace RNS System implanted for epilepsy treatment\n\nExclusion Criteria:\n\n* All DSM-V Axis I and II disorders other than nicotine-dependence\n* History of brain damage","70 Years",{"count":543,"type":20},[23],"Spatial navigation is a fundamental human behavior, and deficits in navigational functions are among the hallmark symptoms of severe neurological disorders such as Alzheimer's disease. Understanding how the human brain processes and encodes spatial information is thus of critical importance for the development of therapies for affected patients. Previous studies have shown that the brain forms neural representations of spatial information, via spatially-tuned activity of single neurons (e.g., place cells, grid cells, or head direction cells), and by the coordinated oscillatory activity of cell populations. The vast majority of these studies have focused on the encoding of self-related spatial information, such as one's own location, orientation, and movements. However, everyday tasks in social settings require the encoding of spatial information not only for oneself, but also for other people in the environment. At present, it is largely unknown how the human brain accomplishes this important function, and how aspects of human cognition may affect these spatial encoding mechanisms. This project therefore aims to elucidate the neural mechanisms that underlie the encoding of spatial information and awareness of others. Specifically, the proposed research plan will determine how human deep brain oscillations and single-neuron activity allow us to keep track of other individuals as they move through our environment. Next, the project will determine whether these spatial encoding mechanisms are specific to the encoding of another person, or whether they can be used more flexibly to support the encoding of moving inanimate objects and even more abstract cognitive functions such as imagined navigation. Finally, the project will determine how spatial information is encoded in more complex real-world scenarios, when multiple information sources (e.g., multiple people) are present. To address these questions, intracranial medial temporal lobe activity will be recorded from two rare participant groups: (1) Participants with permanently implanted depth electrodes for the treatment of focal epilepsy through responsive neurostimulation (RNS), who provide a unique opportunity to record deep brain oscillations during free movement and naturalistic behavior; and (2) hospitalized epilepsy patients with temporarily implanted intracranial electrodes in the epilepsy monitoring unit (EMU), from whom joint oscillatory and single-neuron activity can be recorded.",[597],"Epilepsy Intractable",{"date":580,"type":32},{"date":600,"type":32},"2022-08-06",{"date":602,"type":20},"2027-04-30",{"name":38,"class":39},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":47,"sex":611,"minAge":17,"maxAge":4,"enrollmentInfo":612,"targetDuration":4,"studyType":21,"phases":614,"briefSummary":615,"conditions":616,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":68},"100495290","alcohol-and-heat-of-the-moment-sexual-decision-making-100495290","NCT05729256","Alcohol and \"Heat of the Moment\" Sexual Decision Making","Alcohol and \"Heat of the Moment\" Sexual Decision Making Among MSM: Identifying Mechanisms of Sexual Risk and Promoting Behavior Change Through Brief Intervention","Inclusion Criteria:\n\n* At least 18 years of age\n* Cisgender man who has had condomless anal intercourse with another man in the past 3 months\n* Engaged in heavy drinking (assessed by either weekly National Institute on Alcohol Abuse and Alcoholism guidelines \\[\\> 14 for men\\], and\u002For a heavy drinking episode in the past month \\[\\> 4 drinks on an occasion\\])\n* Has a smartphone\n\nExclusion Criteria:\n\n* HIV-infection\n* Currently using PrEP\n* In an exclusive monogamous sexual relationship\n* History of bipolar disorder, schizophrenia, other psychotic disorder, or current suicidal intent\n* Current treatment for alcohol use disorder or substance use disorder\n* Unable to provide one or more individuals who can serve as an alternate contact","MALE",{"count":613,"type":20},354,[23],"HIV transmission remains a significant public health concern, especially among men who have sex with men (MSM). Condomless anal intercourse (CAI) continues to be the major route of transmission for MSM. Thus, to reduce the incidence of HIV, it is critical to identify how contextual risk factors influence CAI and develop behavioral strategies that modify risk factors directly or reduce their influence on behavior. This study will examine the mechanisms through which one of the central contextual risk factors, heavy drinking, influences sexual decision processes in the natural environment and test the benefit of a brief intervention designed to reduce sexual risk behavior among those who engage in heavy drinking.",[617,618,27],"Alcohol Drinking","Sex, Unsafe","2025-02-06",{"date":621,"type":32},"2025-02-07",{"date":623,"type":32},"2023-11-01",{"date":625,"type":20},"2026-11",{"name":38,"class":39},{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":631,"acronym":4,"eligibilityCriteria":632,"healthyVolunteers":12,"sex":48,"minAge":49,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":21,"phases":635,"briefSummary":636,"conditions":637,"keywords":4,"overallStatus":286,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":645,"locationsCount":68},"100572804","transcranial-stimulation-combined-with-auditory-training-100572804","NCT06738030","Transcranial Stimulation Combined With Auditory Training","Inclusion Criteria:\n\n* 50 years of age or older\n* Audiometric thresholds that do not exceed 90 dB HL at any frequency from 250-6000 Hz\n* Able to provide informed consent and understand experimental instructions\n* Able to read print on a computer screen\n* Difficulty with speech-on-speech understanding\n* Access to computer or mobile phone with access to internet that can play sound (for the at-home training)\n\nExclusion Criteria:\n\n* Non-native speakers of English\n* History of skull fracture, scalp tissue damage, metallic implants around the head, seizures, neurological disorders, or traumatic brain injury, current or suspected pregnancy",{"count":634,"type":20},94,[23],"The goal of this clinical trial is to learn if non-invasive brain stimulation (called transcranial stimulation) can enhance the benefits from auditory training in people who struggle to understand one talker when many people are talking at the same time. The main questions it aims to answer are:\n\n* Does transcranial stimulation improve speech-on-speech understanding in people who struggle with this task?\n* Does transcranial stimulation enhance the benefits of a commercially available auditory training program?\n\nResearchers will compare transcranial stimulation to sham stimulation (no stimulation is applied during the listening task).\n\nParticipants will:\n\n* Receive login information to an online auditory training program to complete at home over 2 weeks\n* Visit the laboratory 4 times to receive transcranial stimulation while listening to speech-on-speech: once before at-home training, two times during the at-home training period, and once after at-home training has ended",[638],"Difficulties Understanding Speech in Noise","2024-12-12",{"date":641,"type":32},"2024-12-17",{"date":643,"type":20},"2025-01-20",{"date":291,"type":20},{"name":38,"class":39},""]